Lifecare confirms 12-week implant stability under real-life conditions materially reduces durability risk ahead of first-in-human study

05 Mar 2026 07:00 CET

Bergen, Norway, 5 March 2026 -- Lifecare ASA (LIFE), a MedTech company
developing next-generation implantable Continuous Glucose Monitoring (CGM)
technology, today announces a significant durability milestone in its ongoing
longevity study.

Following the Q4 2025 report, which marked the transition from
proof-of-concept to system-level validation, Lifecare now reports stable
implant performance beyond 12 weeks of implantation. No structural signal
degradation has been observed.

12 weeks of stable real-life performance represents a meaningful step toward
Lifecare's ambition of long-term, calibration-free implantable glucose
monitoring.

12 weeks completed within six-month framework
In October 2025, Lifecare received regulatory approval permitting implantation
in dogs for up to six months, extending the previous three-month allowance.
The first study cohort completed the planned three-month evaluation confirming
safety and biocompatibility. The second cohort is initiated under the expanded
six-month framework and the first 12 weeks of continuous implantation have now
been successfully completed.

This milestone extends the demonstrated operational window of the implant
within a six-month implantation horizon.

Stable performance in real-life conditions
The animals live as home-dogs outside the clinic under normal activity and
environmental exposure. The data confirms consistent signal generation,
preserved dynamics, reliable wireless communication, and no noise escalation
or signal collapse under these real-life conditions.

An important characteristic of long-term implantable systems is controlled and
predictable signal behaviour. This enables precise modelling and algorithmic
optimisation and supports sustained performance over extended implantation
periods.

Lifecare's implant demonstrates stable signal behaviour over time, with
gradual and predictable drift consistent with expected electrochemical ageing.

This reinforces the durability of the technology and underlines its readiness
for the next phase of development.

Progression toward first-in-human
As previously communicated, the electronics module has achieved CE marking and
ethics approval for first-in-human (FIH) studies is in place, with regulatory
clearance pending. The extended longitudinal data further strengthens system
robustness ahead of human trials. Demonstrating stable signal behaviour over
12 weeks in real-life settings is a key prerequisite for progressing
implantable sensor systems toward human clinical use.

"The key question for any implantable sensor is not only whether it works
initially, but whether it behaves predictably over time," says Joacim Holter,
CEO of Lifecare. "Stable performance beyond 12 weeks in real-life
physiological conditions materially reduces durability risk and supports our
progression toward human studies."

Outlook
The longevity study continues toward the six-month evaluation window. Signal
optimisation and reference benchmarking remain ongoing.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

667533_Lifecare confirms 12-week implant stability under real-life conditions materially reduces durability risk ahead of first-in-human study.pdf